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Background: Primary testicular lymphoma (PTL) is a rare and lethal disease. The most common histological
subtype is diffuse large B-cell lymphoma (DLBCL). Standard treatments are frequently ineffective. Thus, the
development of novel forms of therapy is urgently required. Specific immunotherapy generating immune
responses directed against antigen predominantly expressed by cancer cells such as cancer-testis antigens (CTA)
may provide a valid alternative treatment for patients bearing PTL, alone or in combination with current therapies.
Methods: Three monoclonal antibodies (mAbs), 77B recognizing MAGE-A1, 57B recognizing an epitope shared by
multiple MAGE-A CTA (multi-MAGE-A specific) and D8.38 recognizing NY-ESO-1/LAGE-1 were used for
immunohistochemical staining of 27 PTL, including 24 DLBCL.
Results: Expression of MAGE-A1 was infrequently detectable in DLBCL specimens (12.50%), whereas multi-MAGE-A
and NY-ESO-1/LAGE-1 specific reagents stained the cytoplasms of tumor cells in DLBCL specimens with higher
frequencies (54.17% and 37.50%, respectively) with different expression levels.
Conclusions: These results suggest that MAGE-A and NY-ESO-1/LAGE-1, possibly in combination with other CTA,
might be used as targets for specific immunotherapy in DLBCL.
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Primary testicular lymphoma (PTL) is an uncommon
and deadly disease accounting for 3-9% of testicular neo-
plasms [1]. It is mainly a disease of elderly [1], since it is
the most common testicular malignancy in men aged
over 60 years [2]. Even though bilateral disease also ex-
ists, the usual presentation is a painless unilateral en-
largement of testis [3]. The pathological diagnosis is
mostly obtained after orchiectomy and subsequent histo-
logic examination of the tissue specimen [4]. A majority
of patients presents with localized stage I and II PTL[1].
The most common histological subtype of PTL is diffuse
large B-cell lymphoma (DLBCL) [5-7]. Other histological
subtypes are follicular, plasmocytoma, lymphoblastic and
Burkitt’s like lymphoma [2,8,9].* Correspondence: tvrtkohudolin@gmail.com
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reproduction in any medium, provided the orPrimary testicular DLBCL is a very aggressive malig-
nancy with a poor outcome, and most patients experi-
ence relapse within the first 2 years [10]. Standard
treatments, especially for limited disease, are controver-
sial [6]. Results of first-line treatment based on orchiec-
tomy and including a variety of chemotherapy protocols
such as R-CHOP (Rituximab – cyclophosphamide
hydroxydaunorubicin oncovin prednisone) and/or radi-
ation [10] remain poor[11]. In addition, due to the low
incidence of the disease, there is an obvious lack of pro-
spective studies [12]. Consequently, the development of
innovative treatment options is required.
Active specific tumour immunotherapy generating im-
mune responses directed against antigens predominantly
expressed by cancer cells may provide a valid alternative
treatment for patients bearing PTL, alone or in combin-
ation with current therapies.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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associated antigens expressed in a restricted number of
healthy tissues such as testicular germ cells, thymus and
placenta [13,14], as well as in a large variety of tumors
of unrelated histological origin including lymphoma
[15]. Because of this expression pattern and of their
capability to induce humoral and cellular immune re-
sponses, they are considered as relevant targets in cancer
immunotherapy [16].
Most probably because of low incidence, the expres-
sion of CTA in PTL was not investigated so far. In the
present study, we have evaluated by immunohistochem-
istry (IHC) the expression of different CTA members
in PTL. Our results demonstrate that MAGE-A andTable 1 CTA protein expression in PTL subtypes
Patients Histological
subtype
MAGE-A1(77B mAb) M
% of positive
tumor cells
Staining
score
Staining
intensity
% of po
tumor
1 FL 0 0 0 90
2 SLL 0 0 0 0
3 B-LBL 0 0 0 10
4 DLBCL 0 0 0 0
5 DLBCL 0 0 0 0
6 DLBCL 0 0 0 0
7 DLBCL 100 3 2 0
8 DLBCL 0 0 0 0
9 DLBCL 0 0 0 0
10 DLBCL 0 0 0 0
11 DLBCL 80 3 2 0
12 DLBCL 0 0 0 0
13 DLBCL 10 2 1 0
14 DLBCL 0 0 0 10
15 DLBCL 0 0 0 10
16 DLBCL 0 0 0 10
17 DLBCL 0 0 0 10
18 DLBCL 0 0 0 10
19 DLBCL 0 0 0 10
20 DLBCL 0 0 0 70
21 DLBCL 0 0 0 10
22 DLBCL 0 0 0 10
23 DLBCL 0 0 0 10
24 DLBCL 0 0 0 90
25 DLBCL 0 0 0 80
26 DLBCL 0 0 0 0
27 DLBCL 0 0 0 10
DLBCL (Diffuse Large B-cell Lymphoma), FL (Follicular Lymphoma), SLL (Small Lymp
Staining score (percentage of positive tumor cell): 0 (negative), 1 (<10%), 2 (10–50%
Staining intensity: 0 (negative), 1 (weak), 2 (moderate intensity), 3 (strong intensity)NY-ESO-1/LAGE-1 expression is detectable in the cyto-
plasm of tumor cells from DLBCL specimens. These
results suggest that these antigens might be potentially
used as novel targets for specific immunotherapy.
Methods
Tissue samples
We investigated a consecutive series of 24 samples from
patients diagnosed for DLBCL at the Department of
Urology of the University Hospital of Zagreb (Croatia),
of the Clinical Hospital Center of Rijeka (Croatia), of
the Clinical Hospitals of Split and Osijek (Croatia) from
1998 to 2008. In addition, 3 samples from patients diag-
nosed for follicular lymphoma (FL), small lymphocyticulti-MAGE-A(57B mAb) NY-ESO-1(D8.38 mAb)
sitive
cells
Staining
score
Staining
intensity
% of positive
tumor cells
Staining
score
Staining
intensity
3 2 80 3 1
0 0 0 0 0
0 3 1 0 0 0
0 0 10 2 1
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 100 3 1
0 0 0 0 0
0 3 2 100 3 2
0 3 3 100 3 2
0 3 2 100 3 2
0 3 2 0 0 0
0 3 1 0 0 0
0 3 2 100 3 3
3 1 90 3 1
0 3 2 100 3 2
0 3 3 0 0 0
0 3 2 100 3 1
3 1 0 0 0
3 2 0 0 0
0 0 0 0 0
0 3 1 0 0 0
hocytic Lymphoma), B-LBL (B-Lymphoblastic Lymphoma).
), 3 (>50%).
.
Diffuse large B-cell lymphoma 
NY-ESO-1/LAGE-1
MAGE-A1
Multi-MAGE-A
A
B
C
Figure 1 Immunohistochemical detection of MAGE-A1,
multi-MAGE-A, and NY-ESO-1/LAGE-1 in diffuse large B-cell
lymphoma tissues. DLBCL tissues were stained either with
MAGE-A1 specific mAb 77B (A.), or multi-MAGE-A specific mAb 57B
(B.) or with NY-ESO-1/LAGE-1 specific mAb D8.38 (C.). Representative
staining displaying positivity for these CTA are shown.
Hudolin et al. Journal of Translational Medicine 2013, 11:123 Page 3 of 6
http://www.translational-medicine.com/content/11/1/123lymphoma (SLL) and B-lymphoblastic lymphoma (B-
LBL) were also analyzed. Patients underwent conven-
tional orchiectomy and the testis tissue samples were
processed for histology as described below.
The study was conducted in accordance with the
Declaration of Helsinki and approved by the ethical
committee of the University Hospital Center of Zagreb
(N°8.1-09/67-2).
Identification of testicular lymphomas subtypes
IHC was performed using routine diagnostic methods [17].
Briefly, testicular tumor tissues obtained after orchiectomy
were formalin-fixed, embedded in paraffin and cut into
4 μm thick sections. Haematoxylin and eosin (HE) staining
was used to evaluate morphology. Different lymphoma sub-
types were identified by IHC, based on the expression of
CD20 (clone L26, 1:50 dilution, Dako, Denmark), CD3
(clone F7.2.38, 1:50 dilution, Dako, Denmark), CD10 (clone
56C6, 1:50, dilution Novocastra, UK), Bcl-6 (clone PG-B6p,
1:10 dilution, Dako, Denmark), CD5 (clone 4C7, 1:50 dilu-
tion, Novocastra, UK), Cyclin D1 (clone SP4, 1:25 dilution,
Lab Vision/Neomarkers, Thermo Scientific, Fremont, CA),
Terminal deoxynucleotidyl transferase (TdT, polyclonal,
1:10 dilution, Dako, Denmark)) and Bcl-2 (clone 124, 1:50
dilution, Dako, Denmark) using avidin-biotin method.
All samples were screened for the presence of tumors
by experienced pathologist in the Clinical Hospital
Center Zagreb and classified according to the World
Health Organization (WHO) criteria.
Immunohistochemistry
Formalin-fixed paraffin embedded PTL sections were
stained with MAGE-A1 specific mAb 77B[18], with
multi-MAGE-A specific mAb 57B [19] generated by
using recombinant MAGE-A3 as immunogen and
recognizing an epitope common to highly homologous
MAGE-A3 and MAGE-A4, but also to MAGE-A1, -A2-,
A6 and -A12 molecules, and with NY-ESO-1/LAGE-1
specific mAb D8.38 [20]. Monoclonal antibodies were
used in the form of undiluted hybridoma supernatants.
Briefly, deparaffinized sections were incubated in
citrate buffer (10 mmol/L, pH 6.0), washed with
phosphate-buffered saline (PBS) buffer (pH 7.2). En-
dogenous peroxidase activity was blocked by treatment
with Peroxidase-Blocking Solution Dako REAL™ (Dako,
Denmark) in accordance to the instructions from the
producers. Slides were washed with PBS buffer and incu-
bated for 90 minutes with 77B, 57B, or D8.38 mAbs
undiluted supernatants at room temperature. After PBS
wash, slides were labeled with streptavidin biotin re-
agents (Universal Dako LSAB®, Dako, Denmark) and
washed. Dako Liquid Dab+ Substrate-chromogen system
(Dako, Denmark) was added to the slides before one
wash in distilled water. Nuclei were counterstained usingDako REAL™ Hematoxylin (Dako, Denmark). Slides were
finally washed again with water, dehydrated with alcohol
(96%) and cleared with xylene. Melanomas and testicular
tissues expressing CTAs were used as positive controls
throughout the study, and healthy skin tissue and un-
stained tumor cells served as the negative control.
Samples were then classified based on semi-quantita-
tive 0–3 staining score if the expression of CTAs was
detectable in <10% of tumor cells (score 1), in 10–50%
of tumor cells (score 2), or in >50% of tumor cells
(score 3). Score 0 was attributed to negative samples.
Results
Histological profiles of the patients
Testis tissue sections from twenty-seven adult male ini-
tially referred to urologist for swelling of the testis and
undergoing orchiectomy for PTL from 1998 to 2008
were investigated. According to WHO histological
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27 had DLBCL, 1 had a follicullar lymphoma (FL), 1 had
a small lymphocytic lymphoma (SLL) and 1 had a
B-lymphoblastic lymphoma (B-LBL).
Due to the multi-institutional nature of this study and
the long time frame of the study (10 years), age, Ann
Arbor tumor stage and local invasion status were not
available.
Immunohistochemical detection of CTA in DLBCL tissues
In order to define if CTA might be relevant targets for
specific immunotherapy in DLBCL, we investigated the
expression level of MAGE-A1 protein by IHC on paraf-
fin embedded DLBCL tissues sections using MAGE-A1
specific mAb 77B [18]. MAGE-A1 was detectable in 3 of
24 (12.50%) DLBCL specimens (Table 1). As shown in
Figure 1A, MAGE-A1 had a clear cytoplasmic location,
as already described in melanoma cell line MZ-2 [18].
Staining intensity was weak in 1 and moderate in 2
tumor specimens (Table 1). As shown in Table 1, in one
sample, 10–50% of tumours cells were MAGE-A1 posi-
tive, whereas in the other two over 50% of tumor cells
showed evidence of positive staining.
We concomitantly evaluated multi-MAGE-A specific
staining by using 57B mAb [19]. Positive tumor cells
were detectable in 13 of 24 (54.17%) DLBCL specimens
(Table 1) with a clear cytoplasmic reaction (Figure 1B).
Staining intensity was weak in 4, moderate in 7 and
strong in 2 specimens (Table 1). Staining score (Table 1),
showed that more than 50% of tumor cells (range:
70–100%, Table 1) were MAGE-A positive.
In parallel, we evaluated the expression of NY-ESO-1/
LAGE-1, a CTA known to be expressed notably in tes-
ticular carcinomas [20], using the previously describedFigure 2 Percentages of DLBCL samples showing evidence of positive
from DLBCL tissues were stained, as described in materials and methods, b
were categorized by taking into account the number of positive reactionsNY-ESO-1/LAGE-1 specific mAb D8.38 [20]. As shown
in Table 1 and Figure 1C, NY-ESO-1/LAGE-1 protein
was detectable in the cytoplasm of tumor cells from 9 of
24 (37.50%) DLBCL samples. Staining intensity was
weak in 4, moderate in 4 and strong in 1 tumor speci-
mens (Table 1). As shown in Table 1, except for one
DLBCL tissue displaying only 10% of NY-ESO-1/LAGE-
1 positive tumor cells, all of DLBCL tissues positive for
this antigens showed more than 50% of positive tumor
cells (range: 90–100%, Table 1).
As expected, CTA specific staining was occasionally
detectable simultaneously in neoplastic cells and in nor-
mal spermatogonia (Figure 1.).
Interestingly, the FL was positive for multi-MAGE-A
staining and NY-ESO-1/LAGE-1 and negative for
MAGE-A1 expression. The B-LBL was positive for
multi-MAGE-A but not for MAGE-A1 or NY-ESO-1/
LAGE-1 expression, whereas the SLL was negative for
all CTA under investigation.Co-expression of MAGE-A and NY-ESO-1/LAGE-1 CTA in
DLBCL tissues
Co-expression of NY-ESO-1/LAGE-1 CTA and MAGE-
A members might result of particular interest for the
design of multi-antigen vaccines. Prompted by this con-
sideration, we evaluated the expression of NY-ESO-1/
LAGE-1 as associated with MAGE-A CTA expression in
DLBCL tissues. As shown in Figure 2 and Table 1, 18 of
24 (75.00%) DLBCL specimens showed evidence of posi-
tive staining following incubation with at least one of
the mAbs under investigation and 7 of 24 (29.17%) posi-
tivity to at least two reagents could be observed
(Figure 2).staining upon incubation with CTA specific mAbs. Testis sections
y IHC with 77B, 57b and D8.38 CTA specific mAbs. DLBCL samples
per tissue.
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Diffuse large B-cell lymphoma (DLBCL) is an infrequent
malignancy of the testis [1]. Despite orchiectomy and
the administration of aggressive chemotherapy such as
R-CHOP, the prognosis is very poor [10]. Therefore, the
development of novel treatments is urgently required.
CTA exhibit a restricted normal tissue expression and
a widespread expression in tumors of different histo-
logical origin. Therefore, CTA may serve as targets for
anti-cancer active specific immunotherapy [16]. To date,
several CTA families have been identified including
MAGE-A and NY-ESO-1/LAGE-1[21]. CTA expression
has previously been detected in Reed-Sternberg cells
[22]. Furthermore, non-Hodgkin lymphomas [23] and in
particular cutaneous lymphomas were also found to ex-
press CTA [24]. Most recently, MAGE-A3 gene expres-
sion in peripheral blood has been suggested to represent
an useful marker for the follow-up of patients with
non-Hodgkin lymphoma undergoing chemotherapy [25].
Nevertheless, due to rareness of the disease, nothing is
known about CTA expression in DLBCL so far.
In this study, taking advantage of the availability of
specific mAbs allowing the identification of CTA-
expressing cells in paraffin embedded clinical specimens
[18-20], we investigated the expression of MAGE-A and
NY-ESO-1/LAGE-1 at the protein level in DLBCL
tissues.
Here, we report for the first time CTA expression in
diffuse large B-cell lymphoma. In particular, multi-
MAGE-A and NY-ESO-1/LAGE-1 specific staining is
detectable in the cytoplasm of tumor cells, in more than
half and in more than one third of DLBCL samples, re-
spectively. This finding is of particular interest because
of the co-existence within the same tissue of healthy
cells of the germinal lineage and of neoplastic lymphoma
cells. In addition, our results reveal that one third of
DLBCL specimens are positive for both MAGE-A and
NY-ESO-1 CTA, suggesting that design of multi-antigen
vaccines might be of relevance for DLBCL treatment.
Conclusions
Our work indicates that MAGE-A and NY-ESO-1/
LAGE-1 antigens, possibly in combination with other
CTA, might represent a realistic therapeutic option in
this rare disease.
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